VCYT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

131.73M

+11.04%

0.391

+8.67%

130.43M

+13.94%

0.340

+9.67%

141.33M

+8.58%

0.398

-9.45%

Estimates Revision

The market is revising Upward the revenue expectations for Veracyte, Inc. (VCYT) for FY2025, with the revenue forecasts being adjusted by 1.57% over the past three months. During the same period, the stock price has changed by 22.39%.

Revenue Estimates for FY2025

Revise Upward

+1.57%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+15.4%

In Past 3 Month

Stock Price

Go Up

+22.39%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast VCYT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VCYT is 42.17 USD with a low forecast of 28.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

1 Sell

Moderate Buy

Current: 0.000

Low

28.00

Averages

42.17

High

48.00

Current: 0.000

Low

28.00

Averages

42.17

High

48.00

Guggenheim

Subbu Nambi

NULL -> Buy

maintain

$45 -> $50

2026-01-05

New

Reason

Guggenheim

Subbu Nambi

Price Target

$45 -> $50

2026-01-05

New

maintain

NULL -> Buy

Reason

Guggenheim analyst Subbu Nambi raised the firm's price target on Veracyte to $50 from $45 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for its covered Diagnostics and Life Sciences Tools companies to reflect recent updates from the companies after meetings with management teams.

Morgan Stanley

Tejas Savant

Underweight

maintain

$28 -> $40

2025-11-11

Reason

Morgan Stanley

Tejas Savant

Price Target

$28 -> $40

2025-11-11

maintain

Underweight

Reason

Morgan Stanley analyst Tejas Savant raised the firm's price target on Veracyte to $40 from $28 and keeps an Underweight rating on the shares.

Guggenheim

maintain

2025-11-07

Reason

Guggenheim

Price Target

2025-11-07

maintain

Reason

Guggenheim notes that NCCN guidelines for prostate cancer V3.2026 were released and include updates to the principles of risk stratification and biomarkers sections. The principles of risk stratification tables include only Decipher from Veracyte and the MMAI test from Artera AI for intermediate risk prostate cancer and high-risk/very-high-risk prostate cancer, and only Decipher for BCR post-RP. At first look, the firm says this is an incrementally positive update for Veracyte's Decipher as the test continues to be differentiated from other genomic classifier tests based on robust clinical evidence and inclusion in the principles of risk stratification table. Guggenheim has a Buy rating on Veracyte.

UBS

Lu Li

Buy

maintain

$42 -> $48

2025-11-05

Reason

UBS

Lu Li

Price Target

$42 -> $48

2025-11-05

maintain

Buy

Reason

UBS analyst Lu Li raised the firm's price target on Veracyte to $48 from $42 and keeps a Buy rating on the shares.

Canaccord

Kyle Mikson

Hold

maintain

$40 -> $43

2025-11-05

Reason

Canaccord

Kyle Mikson

Price Target

$40 -> $43

2025-11-05

maintain

Hold

Reason

Canaccord analyst Kyle Mikson raised the firm's price target on Veracyte to $43 from $40 and keeps a Hold rating on the shares. The firm said the company demonstrated strong execution in 3Q25, although they remain on the sidelines until they gain visibility to and confidence in long-term growth drivers.

Canaccord

Kyle Mikson

Hold

initiated

$40

2025-10-20

Reason

Canaccord

Kyle Mikson

Price Target

$40

2025-10-20

initiated

Hold

Reason

Canaccord analyst Kyle Mikson initiated coverage of Veracyte with a Hold rating and $40 price target. The company's Afirma tests for thyroid nodule classification and Decipher tests for risk stratification of prostate cancer could support solid near-term revenue growth, the analyst tells investors in a research note. However, the firm says both markets are highly penetrated and that is is uncertain if Veracyte's test platform transition strategy and pipeline will drive long-term growth.

Valuation Metrics

The current forward P/E ratio for Veracyte Inc (VCYT.O) is 27.39, compared to its 5-year average forward P/E of -14.05. For a more detailed relative valuation and DCF analysis to assess Veracyte Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-14.05

Current PE

27.39

Overvalued PE

1301.62

Undervalued PE

-1329.71

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-52.30

Current EV/EBITDA

22.02

Overvalued EV/EBITDA

96.67

Undervalued EV/EBITDA

-201.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

6.87

Current PS

6.11

Overvalued PS

10.67

Undervalued PS

3.07

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

VCYT News & Events

Events Timeline

No data

News

3.5

2025-12-31Newsfilter

Oncolytics Biotech Achieves 33% Response Rate with Pelareorep in KRAS-Mutant Colorectal Cancer

3.5

2025-12-31PRnewswire

Oncolytics Biotech Reports 33% Response Rate in KRAS-Mutant Colorectal Cancer with Pelareorep

7.0

2025-12-31Yahoo Finance

Veracyte Raises 2025 Sales Guidance to $510 Million Amid Positive Market Trends

People Also Watch

Frequently Asked Questions

What is Veracyte Inc (VCYT) stock price today?

The current price of VCYT is 42.75 USD — it has decreased -1.86 % in the last trading day.

What is Veracyte Inc (VCYT)'s business?

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.

What is the price predicton of VCYT Stock?

What is Veracyte Inc (VCYT)'s revenue for the last quarter?

Veracyte Inc revenue for the last quarter amounts to 131.87M USD, increased 13.82 % YoY.

What is Veracyte Inc (VCYT)'s earnings per share (EPS) for the last quarter?

Veracyte Inc. EPS for the last quarter amounts to 0.24 USD, increased 26.32 % YoY.

What changes have occurred in the market's expectations for Veracyte Inc (VCYT)'s fundamentals?

How many employees does Veracyte Inc (VCYT). have?

Veracyte Inc (VCYT) has 824 emplpoyees as of January 09 2026.

What is Veracyte Inc (VCYT) market cap?

Today VCYT has the market capitalization of 3.44B USD.